CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced the appointment of Lee R. Brettman, M.D., FACP, to the newly created position of chief medical officer. This appointment reflects Alnara’s continued growth as the company prepares to submit a new drug application (NDA) and bring to market liprotamase, a novel, oral, non-porcine pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).
